Jefferies Upgrades Dr. Reddy's Laboratories to Hold from Sell
Investment firm Jefferies has upgraded its rating for Dr. Reddy's Laboratories from 'Sell' to 'Hold' and set a price target of $13.90.
Stocks · News reference
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M Estimate
Dr Reddy's Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In Pydibhimavaram
– Reuters
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth
The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.